The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
Crl123, pls can I politely request that you relent on the city slicker chat, I don't see how it can be helpful for anyone (whether true or not).
I don't see how the sp games (if they so are) can last until Summer if the good news that we are expecting is forthcoming. Even if they do, I will be still be here and will be wishing Porky a happy 70th birthday.
Welcome back Shaun.
And that is out of about 5m tests (based on a quick calculation on the graph on page 4). So if I've got my sums right, there is only a 1.5% chance of an LFT finding a positive case. Value for money?
Good article. Key quotes:
"This new site is part of our ongoing work to expand our testing network across the UK which now has the capacity to process more than 700,000 tests a day. We will continue to expand capacity to improve test turnaround times and push forward testing innovations to make sure anyone who needs a test can get one."
"Testing continues to play an important role how we manage the virus alongside the roll out of vaccines, helping to identify local outbreaks, slow down the rate of transmission and protect communities. "
"Testing is a critical part of the UK’s strategy to combat coronavirus and we’re proud to support the UK Government with this vital task. "
The Justin Waites of this world will soon cotton on.
Include lots of people from NHS, Heathrow Airport, Government official of Netherlands, University of Cambridge, Global category lead at AZN and scientists / companies from all over the world including Indonesia, Thailand, India, Sri Lanka and Greece.
Not too many French names but maybe they are all out at lunch at that time (I miss the guy who used to say that everyday).
Porks you can't really say lets not talk about something and then do a whole post on it! That's the equivalent of saying no offence but...Regardless, I agree and looking forward to the bounce (hopefully not of the dead cat variety this time).
Fantastic find this. Worth a 1000 posts about PR and the direction of travel of the sp. Here is the website link for anyone who has not seen. https://gosafe48.ie/corporate-testing/
Check out the corporate section and the bit about office based businesses which IMO is a potentially massive market for nova. The market is completely oblivious to this (because it is all about LFTs for now and nova have not come out and clearly and directly said this is what the product can do).
Onsite Corporate Coronavirus Testing For Employers & Organisations
The COVID-19 pandemic continues to impact every walk of life including work environments. Companies are looking at strategies to help ensure staff safety and business continuity. We can help. Rapid testing that doesn’t compromise on accuracy, is seen by many as key to social and economic recovery.
?Businesses that run warehouses or manufacturing plants, for instance, can manageably test employees either prior to the start of their shifts or during work hours with little disruption to workflow. Those tested on-site receive results directly to their phone, so as to not infect anyone unknowingly thereafter. Providing test results within 2 hours with 100 percent specificity and 97 percent sensitivity surpassing lab-based tests, our FRANKD’s solution has already helped large companies such as Virgin Atlantic. It became the first airline in the UK to introduce pre-flight COVID-19 testing; initially starting with flights between Shanghai and Hong Kong, the airline extended its services to Barbados in late October.
?We specialise in building custom return to work and testing programs, either as once off exercise or regular testing, catering for 10 to 10,000 employees. We are currently working with airlines, rail companies, cruise ships as well as more office based businesses; law firms, accountancy, big tech etc.
The government's narrative is interesting. It has looked for a while that lft was for asymptomatic and PCR for symptomatic but the recent surge testing makes me think that maybe this will change especially in any parts of the country where a dangerous variant is spreading.
My hope and it is perhaps an unrealistic one (I'm no scientist) is that Lamp testing starts to become preferred to LFTs for asymptomatic cases. We know BAE use lamp testing and these comments re the approval from optigenes test are positive:
Unlike PCR tests, LAMP tests do not require sequential changes of temperature and so can turnaround test results more rapidly.
As part of the strategy to deliver asymptomatic testing to identify those who might otherwise unknowingly spread the virus, OptiGene RT-LAMP tests have been used to test some NHS staff and in asymptomatic testing pilots in Southampton, including at the University of Southampton which has seen 55,000 people tested.
Initial results from these pilots show the test as effective in identifying positive cases and breaking chains of transmission.
Health Minister Lord Bethell said:
With up to a third of individuals with COVID-19 not displaying symptoms, we are rolling out asymptomatic testing to protect those at highest risk. Most importantly NHS staff who are at the forefront of fighting this virus. By broadening testing to identify those showing no symptoms and who can infect people unknowingly, we can find positive cases more quickly and break chains of transmission.
We are using the latest technology to do this, and the country’s leading scientists have rigorously evaluated the Optigene LAMP test in the lab and in the field and confirmed its sensitivity for asymptomatic testing.
Stage set for our lamp test to change the market...
Very good article, thanks for sharing. Great that nova have found a solution to Cog-UK's logistical challenge of collecting samples from so many different laboratories. Does anyone know how closely we have been working with cog UK (I guess we will find out on Feb 26th if not). Apart from the tests, and possibly more sales of q16/ 32s what other revenue streams do you think nova will get from its work in this area? The latest RNS mentions a worldwide surveillance study, will this generate revenue? I also wonder where Pfizer et al are getting their data on the variants from, do nova have a role here?